AOTI Valuation

Is AOTI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AOTI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AOTI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AOTI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AOTI?

Key metric: As AOTI is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for AOTI. This is calculated by dividing AOTI's market cap by their current book value.
What is AOTI's PB Ratio?
PB Ratio	n/a
Book	UK£0
Market Cap	UK£134.01m

AOTI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does AOTI's PB Ratio compare to its peers?

The above table shows the PB ratio for AOTI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2x
EKF EKF Diagnostics Holdings	1.7x	n/a	UK£116.6m
NIOX NIOX Group	3.2x	17.1%	UK£260.3m
CREO Creo Medical Group	1.4x	41.0%	UK£67.4m
AGL ANGLE	1.6x	55.3%	UK£40.3m
AOTI AOTI	n/a	n/a	UK£134.0m

Price-To-Book vs Peers: Insufficient data to calculate AOTI's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does AOTI's PB Ratio compare vs other companies in the GB Medical Equipment Industry?

1 Company	Price / Book	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: Insufficient data to calculate AOTI's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is AOTI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AOTI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AOTI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Guerbet

€339.2m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

-9.8%

50.2%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.92

-4.8%

-9.6%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.06

-6.1%

5.3%